1. In Vivo
  2. >>Innovation

Pharma Spreads Its Bets On Multiple Modalities In Advanced Products

 
• By Pascal Joly, Ana Costa, and Markus Thunecke

Companies such as Novartis, Roche or Takeda are heavily invested in the advanced therapeutics field, usually spreading their bets across multiple modalities. The remaining challenges offer opportunities for the next wave of innovation to transform the field once again and make a dent in the larger market of common diseases and solid tumors.  

Blue Dice

Cell, gene and RNA therapies have been widely adopted by the major pharma players. While their growth is tremendous (52% CAGR up to 2026), they will only account for up to 7% of total market size by 2026.

The US Food and Drug Administration's (FDA) website currently references 23 approved cell and gene therapies, including six CAR-T products,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Astellas’s New Head Of Innovation Lab Sets Fresh Direction For External R&D

 
• By David Wild

Launched in April 2025, Astellas’s Innovation Lab unites fragmented research units under Morten Sogaard to pursue focused indications, a dual-track R&D strategy and tailored partnerships that balance innovation, risk and collaboration.

ResMed Taps Wearables And GLP-1 Trends To Expand Sleep Care

 
• By Marion Webb

Resmed’s CMO Carlos Nunez discusses the sleep giant’s continued push from medtech into healthtech and its efforts to fix what he calls a “broken pathway” to diagnosis and treatment for millions with undetected sleep apnea.

Podcast: The Potential Of AI In Developmental Cell Biology

 
• By David Wild

In this episode, In Vivo speaks with Micha Breakstone, co-founder and CEO of Somite.AI, and Samantha Dale Strasser, VP of strategy, to explore how their techbio is applying foundation models to human cell differentiation.

Pharmatech Funding: What Corporate VCs Actually Want

 
• By David Wild

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.

More from In Vivo

Podcast: The Potential Of AI In Developmental Cell Biology

 
• By David Wild

In this episode, In Vivo speaks with Micha Breakstone, co-founder and CEO of Somite.AI, and Samantha Dale Strasser, VP of strategy, to explore how their techbio is applying foundation models to human cell differentiation.

A Year Of Firsts As Biosimilars Build Momentum In US

 
• By Dave Wallace

In a busy year for US biosimilars, 2025 saw more than a dozen approvals as multiple biologics faced competition for the first time – including Stelara. However, concerns persist over the lack of rivals in development for numerous brands coming off-patent, with a hope that regulatory streamlining can

Pharmatech Funding: What Corporate VCs Actually Want

 
• By David Wild

Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.